NCT01616121

Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 654 (actual)
• Sponsor: Hillel Yaffe Medical Center · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

It is well-known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedance-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.

Conditions

• Heart Failure

Interventions

Type	Name	Description
OTHER	Usual treatment of patients with developing acute heart failure
DEVICE	Lung Impedance-Guided Therapy	Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)

Timeline

• Start date: 2002-06-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2012-06-11
• Last updated: 2020-06-19

Locations

1 site across 1 country: Israel